Networked research infrastructures and their governance: The case of biobanking

Science and Public Policy

Volumn 39, Issue 4, 2012, Pages 491-499

  Meijer, Ingeborg ^a   Molas Gallart, Jordi ^b   Mattsson, Pauline ^c  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Biobanks; Governance; Networking; Research infrastructures

Indexed keywords

EUROPEAN UNION; GOVERNANCE APPROACH; INFRASTRUCTURE PLANNING; MANAGEMENT PRACTICE; NETWORKING;

EID: 84871368144     PISSN: 03023427     EISSN: None     Source Type: Journal    
DOI: 10.1093/scipol/scs033     Document Type: Article

References (34)

1. Bureau of Industry Economics. (1992) Economic Evaluation of CSIRO Industrial Research: Overview of Case Studies. Melbourne: Australian Government Productivity Commission.
2. Burton, P. R., Hansell, A. L., Fortier, I., Manolio, T. A. et al. (2009) 'Size matters: just how big is BIG? Quantifying realistic sample size requirements for human genome epidemiology', International Journal of Epidemiology, 38: 263-73.
3. Cambon Thomsen, A. (n.d.) 'Overall Report and Recommendations for BBMRI ELSI, Including Educational Proposals', BBMRI Deliverable D6.10. accessed 14 Dec 2011.
4. Bressan, B., ed., (2005) CERN CERN Technology Transfers to Industry and Society. Geneva: CERN.
5. Chadwick, R. (1999) 'The Icelandic database: Do modern times need modern sagas?', British Medical Journal, 319: 441-4.
6. Chadwick, R. and Strange, H. (2009) 'Harmonisation and standardisation in ethics and governance: conceptual and practical challenges'. In: Widdows, H. and Mullen, C. (eds) The Governance of Genetic Information: Who Decides? pp. 201-13. Cambridge: CUP.
7. Collins, F. S., Green, E. D., Guttmacher, A. E. and Guyer, M. S. (2003) 'A vision for the future of genomics research', Nature, 422: 835-47.
8. Editorial. (2009) 'Biobank needs pharma', Nature, 462: 448.
9. EPPOSI. (2006) Towards Joint Ventures of Patient Organizations, Science and Industry on the Road to Validated Expertise and New Therapies. Amsterdam: EPPOSI.
10. European Commission. (2010) Europeans and Biotechnology in 2010. Brussels: European Commission.
11. Gaskell, G. and Gottweis, H. (2011) 'Biobanks need publicity', Nature, 471: 159-60.
12. Gottweis, H. (2005) 'Governing genomics in the 21st century: Between risk and uncertainty', New Genetics and Society, 24: 175-93.
13. Gottweis, H. and Zatloukal, K. (2007) 'Biobank governance: Trends and perspectives', Pathobiology, 74: 206-11.
14. Gottweis, H., Haidan Chen, H. and Starkbaum, J. (2011) 'Biobanks and the phantom public', Human Genetics, 130: 433-40.
15. Groenewegen, P. and Wouters, P. (2004) 'Genomics, ICT and the formation of R&D networks', New Genetics and Society, 23: 167-85.
16. Hagen, H. E. and Carlstedt-Duke, J. (2004) 'Building global networks for human diseases: Genes and populations', Nature Medicine, 10: 665-7.
17. Hallonsten, O., Benner, M. and Holmberg, G. (2004) Impacts of Large-scale Research Facilities - a Socio-economic Analysis. RPI Discussion paper 1/2004, Lund University.
18. Hansson, M. G. (2011) 'Biobanking within the European Regulatory Framework: Opportunities and obstacles', Biopreservation and Biobanking, 9: 165-7.
19. Hirtzlin, I., Dubreuil, C., Préaubert, N., Duchier, J. et al. (2003) 'An empirical survey on biobanking of human genetic material and data in six EU countries', European Journal of Human Genetics, 1: 475-88.
20. Hoheisel, J. D. (2006) 'Microarray technology: beyond transcript profiling and genotype analysis', Nature Reviews Genetics, 7: 200-10.
21. International Data Corporation. (2004) 'Biobanks: Accelerating molecular medicine: Challenges Facing the Global Biobanking Community'. Framingham, MA: International Data Corporation.
22. Johnsson, L., Hansson, M. G., Eriksson, S. and Helgesson, G. (2008) 'Opt-out from biobanks better respects patients' autonomy', British Medical Journal, 337: a1580.
23. Juhlin, M., Korpelainen, S., Höltge, K., Akre, B. et al. (2009) Evaluation of the Pertinence and Impact of the EU Support Actions to Research Infrastructures in the 6th Framework Programme. Technical Appendices. London: Matrix Insight, Ramboll.
24. Laurie, G. (2008) 'Evidence of support for biobanking practices', British Medical Journal, 337: a337.
25. Malsch, I. (1997) 'The Importance of Interdisciplinary Approaches: The Case of Nanotechnology', IPTS Report No. 13. IPTS: Seville, Spain.
26. Manolio, T. A., Bailey-Wilson, J. E. and Collins, F. S. (2006) 'Genes, environment and the value of prospective cohort studies', Nature Reviews Genetics, 7: 812-20.
27. Mayrhofer, M. (2010) 'Biobanks in Practice. A Comparative Perspective', PhD thesis, Universitä t Wien
28. Meijer, I., Mattson, P., Molas-Gallart, J., Boekholt, P. et al. (2010) BBMRI: an Evaluation Strategy for Socio-economic Impact. Amsterdam: Technopolis.
29. OECD. (1995) Cost/Benefit Analysis of Large Scale S&T Projects: Notes on Some Methodological Issues. Paris: OECD.
30. Porcheray, C. and Lavocat, P. (2008) 'European Research Infrastructures Development Watch (ERID-Watch)', Deliverable D-10: Policy Recommendations. accessed 21 Dec 2011.
31. Tutton, R. (2007) 'Banking expectations: reflections on the promises of biobanks', Personalised Medicine, 4: 463-9.
32. Yuille, M., Dixon, K., Platt, A., Pullum, S. et al. (2010) 'The UK DNA banking network: a "fair access"biobank', Cell Tissue Bank, 11: 241-51.
33. Zika, E., Schulte in der Baumen, T., Kaye, J., Brand, A. and Ibarreta, D. (2008) 'Sample, data use and protection in biobanking in Europe: legal issues', Pharmacogenomics, 9: 773-81.
34. Zuijdam, F., Boekholt, P., Deuten, J., Meijer, I. and Vermeulen, N. (2011) The Role and Added Value of Large-scale Research Facilities. Amsterdam: Technopolis.